DETERMINING THE VALUE OF EMICIZUMAB (HEMLIBRA (R)) FOR THE PROPHYLAXIS TREATMENT OF HAEMOPHILIA A PATIENTS WITH INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Por: Alvarez, M, Cuervo-Arango, I, Perez-Santamarina, R, Poveda, J, Romero, J, Santamaria, A, Trillo, J, Tort, M and Badia, X

---

Publicada: 1 oct 2018

---

---

Filiaciones:
Alvarez, M:
 Hosp Univ La Paz, Madrid, Spain

Cuervo-Arango, I:
 Roche Farma SA, Madrid, Spain

Perez-Santamarina, R:
 Hosp Univ La Paz, Madrid, Spain

Poveda, J:
 Hosp 12 Octubre, Madrid, Spain

Romero, J:
 Hosp Univ La Paz, Madrid, Spain

:
 Hosp Univ Vall dHebron, Barcelona, Spain

:
 Valencia Hlth Dept Clin Malvarrosa, Valencia, Valencia, Spain

 Former Director Gen Pharm, Valencia, Valencia, Spain

Tort, M:
 Omakase Consulting, Barcelona, Spain

Badia, X:
 Omakase Consulting, Barcelona, Spain